Drug Profile
Respiratory syncytial virus vaccine - Okairos AG
Alternative Names: PanAd3-RSV; RSV 001; RSV vaccine - Okairos AGLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Okairos AG
- Class Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention) in United Kingdom (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(Prevention) in United Kingdom (Intranasal)
- 29 May 2013 Okairos has been acquired by GlaxoSmithKline